TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,684,560 | -0.2% | 524,000 | +71.4% | 0.04% | -10.0% |
| Q2 2023 | $4,694,461 | -27.5% | 305,629 | +6.2% | 0.04% | -35.5% |
| Q1 2023 | $6,471,676 | +839.3% | 287,758 | +929.0% | 0.06% | +933.3% |
| Q3 2022 | $689,000 | -30.8% | 27,964 | -32.0% | 0.01% | -40.0% |
| Q2 2022 | $996,000 | +250.7% | 41,109 | +273.7% | 0.01% | +233.3% |
| Q1 2022 | $284,000 | -30.2% | 11,000 | -16.0% | 0.00% | -25.0% |
| Q4 2021 | $407,000 | +73.2% | 13,100 | +35.1% | 0.00% | +100.0% |
| Q3 2021 | $235,000 | -26.6% | 9,700 | -55.8% | 0.00% | -33.3% |
| Q2 2021 | $320,000 | -90.4% | 21,960 | -82.1% | 0.00% | -93.3% |
| Q4 2020 | $3,348,000 | – | 122,819 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |